drug
dasiglucagon
Marketedupdated 3mo agoby Novo Nordisk Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying dasiglucagon
- phase3Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
- phase1Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
- phase3A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
- phase3Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
- phase2A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
- phase3A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 6, 2034
~7.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Feb 3, 2035compositionUS 10442847
- Jan 6, 2034method-of-use (U-3752)US 11795204
FDA exclusivities (1)
- Mar 22, 2026NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that